WBB Securities restated their strong-buy rating on shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a report issued on Tuesday morning. They currently have a $60.00 price target on the stock, up from their prior price target of $40.00.

Other research analysts also recently issued research reports about the company. Oppenheimer Holdings Inc. raised their target price on Sarepta Therapeutics from $60.00 to $76.00 in a research note on Monday. Vetr upgraded Sarepta Therapeutics from a strong sell rating to a buy rating and set a $17.28 target price for the company in a research note on Thursday, June 2nd. Robert W. Baird restated a buy rating on shares of Sarepta Therapeutics in a research note on Friday, June 10th. Needham & Company LLC raised their target price on Sarepta Therapeutics from $20.00 to $26.00 and gave the stock a buy rating in a research note on Friday, July 22nd. Finally, Janney Montgomery Scott upgraded Sarepta Therapeutics from a neutral rating to a buy rating and raised their target price for the stock from $30.00 to $65.00 in a research note on Monday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Sarepta Therapeutics has an average rating of Buy and an average price target of $48.70.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 60.97 on Tuesday. The stock’s 50 day moving average price is $30.01 and its 200 day moving average price is $21.91. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $61.60. The company’s market capitalization is $2.92 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same period last year, the company posted ($0.87) earnings per share. On average, equities research analysts forecast that Sarepta Therapeutics will post ($4.17) earnings per share for the current year.

In related news, SVP David T. Howton sold 9,304 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $50.00, for a total transaction of $465,200.00. Following the sale, the senior vice president now directly owns 11,168 shares in the company, valued at $558,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jayant Aphale sold 35,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $1,750,000.00. Following the sale, the vice president now owns 21,490 shares in the company, valued at $1,074,500. The disclosure for this sale can be found here. Corporate insiders own 10.90% of the company’s stock.

Several large investors have recently added to or reduced their stakes in SRPT. Harbour Capital Advisors LLC purchased a new stake in Sarepta Therapeutics during the second quarter valued at $335,000. Schwab Charles Investment Management Inc. raised its stake in Sarepta Therapeutics by 1.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 153,816 shares of the company’s stock valued at $2,934,000 after buying an additional 2,766 shares in the last quarter. Stifel Financial Corp raised its stake in Sarepta Therapeutics by 5.4% in the second quarter. Stifel Financial Corp now owns 23,076 shares of the company’s stock valued at $441,000 after buying an additional 1,178 shares in the last quarter. American Century Companies Inc. purchased a new stake in Sarepta Therapeutics during the second quarter valued at $651,000. Finally, First Allied Advisory Services Inc. raised its stake in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares in the last quarter. Institutional investors own 72.09% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.